Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
12   Dr. Jin-San Yoo, CEO of PharmAbcine is presenting PharmAbcine`s R&D progress and the interim data of the ongoing phase IIa recurrent GBM trial at 2017 Bio International Convention in San Diego on June 19-22, 2017.   Admin   2019-01-14   698  
11   Dr. Lawrence Cher, principle investigator of Tanibirumab phase IIa recurrent GBM trial in Australia expose the interim data of the ongoing trial at ASCO 2017 Annual Meeting in Chicago on June 2-6, 2017.   Admin   2019-01-14   722  
10   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present PharmAbcine`s R&D progress at BIO LOGISTICS WORLD KOREA in Seoul on May 23-24, 2017.   Admin   2019-01-14   747  
9   Dr. Jin-San Yoo, CEO of PharmAbcine is serving as an expert of MAB working group of EDQM observer representing Republic of Korea.   Admin   2019-01-14   736  
8   Dr. Jin-San Yoo, CEO of PharmAbcine is serving as an officer for Bio at the Med term Strategy and planning for pharma industry.   Admin   2019-01-14   10,612  
7   Dr. Jin-San Yoo, CEO of PharmAbcine will be awarded for the contribution of Health-Medical by KHIDI President on April 13th, 2017.   Admin   2019-01-14   611  
6   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present at ``BizForum`` at BioKorea 2017.   Admin   2019-01-14   584  
5   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present at ``HI KOREA INVEST FAIR 2017``   Admin   2019-01-14   701  
4   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present at BioPharm Asia in Singapore on March 21st-23rd, 2017.   Admin   2019-01-14   663  
3   Dr. Jin-San Yoo, CEO of PharmAbcine is invited as plenary panelist at BioAsia in Tokyo, Japan on March 14th-15th, 2017.   Admin   2019-01-14   652